Abstract
As an alternative to liver biopsy, an index of five biochemical markers (α2-macroglobulin, apolipoprotein A1, haptoglobin, total bilirubin, γ-glutamyl-transpeptidase) has been shown to predict the severity of hepatitis C-related fibrosis. The objective of this study was to compare this index with other markers frequently used for this purpose (prothrombin time, platelets, age–platelet index). In 323 hepatitis C-infected patients, the discriminative values of these markers for F2–F4 fibrosis (by the METAVIR classification) were compared. By multiple logistic regression analysis, only the five-marker index (P < 0.0001) and prothrombin time (P = 0.02) were independently predictive of F2–F4 fibrosis. For this outcome, the area under the receiver operating characteristic curve was significantly higher for the five-marker index (0.836 ± 0.024) than the age-platelet index (P = 0.002), and the platelet count and prothrombin time (P < 0.001), indicating greater diagnostic value. The addition of the latter markers to the five-marker index proved unhelpful for increasing its accuracy. In conclusion, an index of five biochemical markers accurately predicts significant hepatitis C-related fibrosis and is superior to traditional markers.
Similar content being viewed by others
REFERENCES
Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med;345:41-52, 2001
Khan MH, Farrell GC, Byth K, Lin R, Weltman M, George J, Samarasinghe D, Kench J, Kaba S, Crewe E, Liddle C: Which patients with hepatitis C develop liver complications? Hepatology 31:513-520, 2000
Perrillo RP: The role of liver biopsy in hepatitis C. Hepatology;26:57S-61S, 1997
EASL International Consensus Conference on Hepatitis C: Paris, February 26-27, 1999. Consensus statement. J Hepatol 31:3-8, 1999
Cadranel JF, Rufat P, Degos F: Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 32:477-481, 2000
Froehlich F, Lamy O, Fried M, Gonvers JJ: Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland. Dig Dis Sci 38:1480-1484, 1993
McGill DB, Rakela J, Zinsmeister AR, Ott BJ:A21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 99:1396-1400, 1990
Perrault J, McGill DB, Ott BJ, Taylor WF: Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology 74:103-106, 1978
Friedman SL, Maher JJ, Bissell DM: Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference. Hepatology 32:1403-1408, 2000
Friedman SL: Evaluation of fibrosis and hepatitis C. Am J Med 107:27S-30S, 1999
Park GJ, LinBP, Ngu MC, Jones DB, Katelaris PH: Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? J Gastroenterol Hepatol 15:386-390, 2000
Wong VS, Hughes V, Trull A, Wight DG, Petrik J, Alexander GJ: Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat 5:187-192, 1998
Walsh KM, Timms P, Campbell S, MacSween RN, Morris AJ: Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and-2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci 44:624-630, 1999
Poynard T, Bedossa P: Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 4:199-208, 1997
PoynardT, Aubert A, Bedossa P, Abella A, Naveau S, Paraf F, Chaput JC: A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 100:1397-1402, 1991
Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357:1069-1075, 2001
Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24:289-293, 1996
National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 26:2S-10S, 1997
Hanley JA, McNeil BJ: A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839-843, 1983
Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 34:730-739, 2001
Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349:825-832, 1997
Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, Matsumoto K, Nakamura T, Takahashi H, Okamoto E, Fujimoto J: Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 5:226-230, 1999
Guillen MI, Gomez-Lechon MJ, Nakamura T, Castell JV: The hepatocyte growth factor regulates the synthesis of acute-phase proteins in human hepatocytes: divergent effect on interleukin-6-stimulated genes. Hepatology 23:1345-1352, 1996
Bacq Y, Schillio Y, Brechot JF, De Muret A, Dubois F, Metman EH: Decrease of haptoglobin serum level in patients with chronic viral hepatitis C. Gastroenterol Clin Biol 17:364-369, 1993
Kanzler S, Lohse AW, Keil A, Henninger J, Dienes HP, Schirmacher P, Rose-John S, zum Buschenfelde KH, Blessing M: TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol 276:G1059-1068, 1999
Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, Purdie DM, Jonsson JR: Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31:828-833, 2000
Tiggelman AM, Boers W, Moorman AF, de Boer PA, Van der Loos CM, Rotmans JP, Chamuleau RA: Localization of alpha 2-macroglobulin protein and messenger RNA in rat liver fibrosis: evidence for the synthesis of alpha 2-macroglobulin within Schistosoma mansoni egg granulomas. Hepatology 23:1260-1267, 1996
Kawser CA, Iredale JP, Winwood PJ, Arthur MJ: Rat hepatic stellate cell expression of alpha2-macroglobulin is a feature of cellular activation: implications for matrix remodelling in hepatic fibrosis. Clin Sci (Colch) 95:179-186, 1998
Albanis E, Friedman SL: Hepatic fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis 5:315-334, v-vi, 2001
Bedossa P, Poynard T, Abella A, Aubert A, Pignon JP, Naveau S, Leluc R, Lemaigre G, Martin ED, Chaput JC: Apolipoprotein AI is a serum and tissue marker of liver fi-brosis in alcoholic patients. Alcohol Clin Exp Res 13:829-833, 1989
Paradis V, Mathurin P, Ratziu V, Poynard T, Bedossa P: Binding of apolipoprotein A-I and acetaldehyde-modified apolipoprotein A-I to liver extracellular matrix. Hepatology 23:1232-1238, 1996
Myers RP, Benhamou Y, Bochet M, Imbert-Bismut F, Thibault V, Ratziu V, Charlotte F, Katlama C, Poynard T: Serum biochemical markers of liver fibrosis in human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-coinfected patients. J Hepatol 36:A50, 2002 (abstract)
Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, Messous D, Degos F: Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. The GERMED cyt-04 group. J Viral Hepat 9:128-133, 2002
Adams L, Rossi E, DeBoer B, Speers D, Macquillan G, Garas G, Jeffrey G: Use of fibrotest to predict liver fibrosis in hepatitis C: A replacement for liver biopsy? Gastroenterology, 122:159A, 2002 (abstract)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Myers, R.P., de Torres, M., Imbert-Bismut, F. et al. Biochemical Markers of Fibrosis in Patients with Chronic Hepatitis C: A Comparison with Prothrombin Time, Platelet Count, and Age–Platelet Index. Dig Dis Sci 48, 146–153 (2003). https://doi.org/10.1023/A:1021702902681
Issue Date:
DOI: https://doi.org/10.1023/A:1021702902681